Additional Relevant Details MBX-8025 is an oral, potent and selective PPARδ agonist with an anti-atherogenic profile that recently finished a Phase 2 study that demonstrated efficacy "in patients with homozygous familial hypercholesterolemia (HoFH, an autosomal genetic disease characterized by loss-of-function mutations in both alleles of the LDL receptor gene)".  CymaBay has expanded the development of MBX-8025 with a Phase 2 study testing the drug in patients with Primary Biliary Cholangitis (PBC).  The study is expected to complete in the fourth quarter of 2016.